Lexeo Therapeutics (LXEO) Expected to Release Quarterly Earnings on Thursday

Posted by George Bondi on Aug 6th, 2026

Lexeo Therapeutics (NASDAQ:LXEO – Get Free Report) will likely be issuing its Q2 2026 results before the market opens on Thursday, August 13th. Analysts expect the company to post earnings of ($0.30) per share for the quarter. Parties are encouraged to explore the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Monday, August 10, 2026 at 9:30 AM ET.

Lexeo Therapeutics (NASDAQ:LXEO – Get Free Report) last released its earnings results on Monday, May 11th. The company reported ($0.25) earnings per share for the quarter, beating the consensus estimate of ($0.29) by $0.04. On average, analysts expect Lexeo Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Lexeo Therapeutics Stock Performance

NASDAQ:LXEO opened at $4.45 on Thursday. The stock’s fifty day moving average is $4.64 and its 200 day moving average is $5.75. Lexeo Therapeutics has a fifty-two week low of $3.99 and a fifty-two week high of $10.99. The firm has a market capitalization of $349.42 million, a PE ratio of -3.07 and a beta of 1.46.

Insiders Place Their Bets

In other Lexeo Therapeutics news, insider Narinder Pal Bhalla sold 22,306 shares of the stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $4.42, for a total value of $98,592.52. Following the sale, the insider owned 82,194 shares in the company, valued at $363,297.48. This trade represents a 21.35% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Richard Nolan Townsend sold 25,947 shares of Lexeo Therapeutics stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $4.48, for a total value of $116,242.56. Following the sale, the chief executive officer owned 377,817 shares of the company’s stock, valued at approximately $1,692,620.16. This trade represents a 6.43% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders have sold 62,204 shares of company stock valued at $280,089. 2.00% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in LXEO. California State Teachers Retirement System increased its stake in Lexeo Therapeutics by 123.7% in the 4th quarter. California State Teachers Retirement System now owns 3,884 shares of the company’s stock worth $39,000 after buying an additional 2,148 shares during the period. Russell Investments Group Ltd. boosted its position in Lexeo Therapeutics by 160.2% in the 4th quarter. Russell Investments Group Ltd. now owns 5,872 shares of the company’s stock valued at $58,000 after buying an additional 3,615 shares during the period. Cerity Partners LLC bought a new position in Lexeo Therapeutics in the 2nd quarter worth about $50,000. Scientech Research LLC bought a new position in Lexeo Therapeutics in the 3rd quarter worth about $90,000. Finally, Intech Investment Management LLC grew its stake in Lexeo Therapeutics by 19.5% in the 4th quarter. Intech Investment Management LLC now owns 14,188 shares of the company’s stock worth $141,000 after acquiring an additional 2,317 shares in the last quarter. 60.67% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of research firms have weighed in on LXEO. Chardan Capital upgraded shares of Lexeo Therapeutics to a “strong-buy” rating in a research report on Tuesday, July 28th. Wall Street Zen upgraded shares of Lexeo Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, May 16th. Weiss Ratings cut shares of Lexeo Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, July 30th. Finally, JPMorgan Chase & Co. cut their price target on shares of Lexeo Therapeutics from $12.00 to $9.00 and set an “overweight” rating on the stock in a report on Thursday, June 25th. Two analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $18.75.

Check Out Our Latest Analysis on Lexeo Therapeutics

About Lexeo Therapeutics

(Get Free Report)

Lexeo Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to developing novel, precision‐designed therapies for central nervous system disorders. The company’s research platform leverages advanced medicinal chemistry to create next‐generation psychedelic-inspired compounds aimed at treating a range of mental health conditions, including anxiety, depression and substance use disorders.

The company’s pipeline features proprietary synthetic molecules engineered to target specific neural pathways while improving safety and tolerability profiles over traditional treatments.